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Toxins have been thoroughly studied for their use as therapeutic agents in
search of an improvement in toxic efficiency together with a minimization
of their undesired side effects. Different studies have shown how toxins can
follow different intracellular pathways which are connected with their cyto-
toxic action inside the cells. The work herein presented describes the differ-
ent pathways followed by the ribotoxin a-sarcin and the fungal RNase T1,
as toxic domains of immunoconjugates with identical binding domain, the
single chain variable fragment of a monoclonal antibody raised against the
glycoprotein A33. According to the results obtained both immunoconju-
gates enter the cells via early endosomes and, while a-sarcin can translocate
directly into the cytosol to exert its deathly action, RNase T1 follows a
pathway that involves lysosomes and the Golgi apparatus. These facts con-
tribute to explaining the different cytotoxicity observed against their tar-
geted cells, and reveal how the innate properties of the toxic domain, apart
from its catalytic features, can be a key factor to be considered for immu-
notoxin optimization.
Introduction
Immunotoxins embody the idea proposed by Paul Ehr-
lich when he defined as magic bullets agents with the
ability to specifically target just one kind of cells and
therefore exert a highly specific therapeutic action
without any unwanted side effects [1]. They are chime-
ric proteins composed of two domains: the target
domain, usually a whole antibody or a fragment which
specifically targets a tumor marker, and the toxic
domain, responsible for the cytotoxicity [2,3]. Three
major types of toxins are used as toxic domains,
depending on their mode of action [4]. Type I consists
of enzymes that interact with the lipidic component of
the membranes and, once inside the cells, modify intra-
cellular functions causing cell death. Type II refers to
toxins that, after binding to a cellular receptor, are
internalized and then kill the cells. Type III involves
those toxins capable of forming pores in the cellular
membrane, leading to cell death. Thus, many different
toxins have been used to construct immunotoxins, e.g.
ricin chain A [5], nigrin b [6], gelonin [7], saporin [8],
Diphtheria toxin [9], Pseudomonas toxin [10], anthrax
toxin [11], barnase [12] or a-sarcin [13], which behave
as type I toxins. On the other hand, tumor necrosis
factor [14] and sTRAIL [15] are type II toxins, while
actinoporins [16,17], cyt A endotoxin [18] and cecropin
belong to the group of type III toxins.
The in vitro toxicity of an immunotoxin depends on
several molecular aspects, including antigen binding
affinity, internalization rate, intracellular processing,
toxin release and intrinsic toxicity [19]. Intracellular
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trafficking of the toxin appears to be a checkpoint for
the desired cytotoxic effects [20]. Once they have
entered cells, protein toxins are found in early endo-
somes that can be later recycled or degraded in the
lysosomes. Subsequent intracellular trafficking, release
and endosomal escape are often achieved using intrin-
sic toxin features. Two main pathways are usually fol-
lowed, direct translocation to the cytosol or the
retrograde route via the Golgi apparatus. Thus, the
ability to deliver the toxin to the cytosol is commonly
considered to be the rate-limiting step in cytotoxic effi-
ciency [7].
Clinical trials using immunotoxins have led to stud-
ies regarding their optimization focused on both target
and toxic domains, although the target domain is the
one which has evolved more over the years [3,21,22].
Thus, immunotoxins were initially designed containing
the entire antibody which soon was replaced by the
Fab domain, the single chain variable fragment (scFv)
or even solely two antibody complementary determi-
nant regions, aiming to achieve size optimization
[3,23–25]. Along with these studies, others have
focused on the stability of the construct [26], the use
of different coadjuvants [27–29] or modifications to
improve specificity by combining two or more different
binding domains to obtain diabodies or triabodies [30–
32].
Within the last decade, new proteins have also
emerged to be used as toxic domains. Using this idea,
RNases from different sources have become a very
popular choice, giving rise to what has been called the
group of immunoRNases [33–35]. The use of proen-
zymes which only become toxic once they are activated
inside the cell [36] is another promising approach.
However, few studies have focused on increasing the
efficiency of the toxic domain [37] or modulating its
intracellular trafficking [38].
The immunoconjugates studied here use as binding
domain the scFv portion of a monoclonal antibody
(scFVA33) which targets the tumor specific antigen
GPA33, a membrane glycoprotein overexpressed in
95% of colon cancer cells and absent in other types of
tumor or healthy tissues [39]. The role of this antigen
is still unknown, although it is thought to be involved
in keeping the mucosal integrity of the small intestine
during embryonic development [40]. In addition, the
intracellular pathway of the internalized antigen
remains unknown except for the fact that it could hap-
pen via macropinosomes [41]. This binding domain
was combined to two different, but structurally
related, RNases as toxic domains. In the first design,
scFvA33 was linked to the fungal ribotoxin a-sarcin
[42] giving as a result the IMTXA33aS immunotoxin
[13]. The second immunoRNase linked the same bind-
ing domain to fungal RNase T1 [43], resulting in the
scFvA33T1 construct [44]. Both immunoRNases have
been characterized in great detail from the structural
and functional points of view [13,44] and thus repre-
sent excellent models to study the effect of intracellular
trafficking on immunotoxin cytotoxicity. Accordingly,
the work presented now focuses on the different path-
ways followed by the two toxic domains and demon-
strates how they determine the different cytotoxic
effectiveness observed between them.
Results
Immunotoxin and immunoRNase labeling
In order to study the binding and routes followed by
the two constructs, the chimeric proteins were labeled
with Alexa 555. The immunoRNase was labeled at pH
8.0, but the immunotoxin was labeled at pH 7.0 given
A
B
Fig. 1. Far-UV CD spectra of (A) IMTXA33aS and (B) scFvA33T1.
In both cases the solid line corresponds to the unlabeled protein,
while the spectra of the proteins labeled with Alexa 555 appear as
dashed lines.
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that a-sarcin is partially denatured around that pH
value [45] and assuming that the lower degree of label-
ing would be compensated by the presence of 17 amine
groups more than the immunoRNase, as RNase T1 is
an acidic protein [43]. Once both constructs were
labeled, far-UV CD spectra were registered in order to
compare the conformations of both the unlabeled and
labeled molecules. As can be seen in Fig. 1, both mod-
ified proteins remain fully structured as the unlabeled
versions.
Internalization studies
Binding of the two immunoconjugates to SW1222 cells
has been reported previously [13,44]. Thus, internaliza-
tion of both labeled constructs was studied after incu-
bation for 16 h. The images obtained (Fig. 2) showed
how both chimeric proteins, immunotoxin and immun-
oRNase, were internalized into the target cells. In
addition, and only in the case of IMTXA33aS, the im-
munoconjugate sometimes appeared within large sized
vesicles (data not shown), previously described as mac-
ropinosomes [41].
Endosome colocalization
To describe the intracellular pathway in more detail,
colocalization with endosomes was also studied. With
this purpose, endosomes were labeled using an
antibody targeting the protein A1, present in early en-
dosomes [46]. As shown in Fig. 3, the results indicated
partial colocalization of both immunoconjugates with
early endosomes. Quantitative colocalization analysis
showed values between 10% and 30% of colocaliza-
tion. Arrows on the figure show some examples where
colocalization with endosomes was found. In this case,
no significant differences were found between the two
immunoconjugates.
Lysosomes–Golgi colocalization
As described above, two main pathways are usually
followed by toxins once they are localized in endo-
somes: via lysosomes or via the Golgi apparatus. To
distinguish between the two organelles, different mark-
ers were used as described in Materials and methods:
LysoTracker, a fluorescent acidotropic probe specific
to lysosomes [47], and wheat germ agglutinin, which
recognizes the highly abundant sialic acid of Golgi
membranes [48]. The images obtained for lysosomes
are shown in Figs 4 and 5. Partial colocalization was
found between the immunoRNase and lysosomes.
Quantitative analysis of the degree of colocalization, at
the two times assayed, showed values around 50% of
colocalization. This degree of colocalization was dra-
matically decreased when the antibiotic bafilomycin,
which inhibits lysosomal acidification, was added
(Fig. 4). However, no colocalization was observed with
A1 A2
B1 B2
C1 C1
D1
D2
Fig. 2. Immunofluorescence microscopy
images of SW1222 cells incubated with
IMTXA33aS-555 (1) or scFvA33T1-555 (2),
25 lgmL1, for 16 h to analyze protein
internalization. (A) DAPI staining of nuclei;
(B) plasmatic membrane staining using
anti-CD44 and GAM-Alexa 647; (C)
fluorescence corresponding to
IMTXA33aS-555 or scFvA33T1-555. (D)
Images corresponding to merging of the
three channels.
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the a-sarcin based immunotoxin at the two times
assayed (Fig. 5).
On the other hand, when the same experiment was
developed using the Golgi-specific probe, colocaliza-
tion was found for both immunotoxin and immun-
oRNase (Fig. 6), the fluorescence signal being more
intense for the latter, with degrees of colocalization
around 45% and 65%, respectively, for the longest
time assayed.
Cell viability assay
There is an inner relationship between the internal
pathway followed by toxins and the lethality of the
immunoconjugates. Accordingly, once the pathway
followed by each construct was studied, we pro-
ceeded to analyze their toxic action. This specific
cytotoxicity had been previously reported, obtaining
IC50 values in the nanomolar range for the a-sarcin
based immunotoxin [13] and in the micromolar
range for the immunoRNase [44]. These assays, how-
ever, were performed in different conditions for the
two immunoconjugates given that the two toxic
domains employed have different mechanisms of
action [42,43,49]. Therefore, cell viability experi-
ments [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetra-
zolium bromide (MTT) or protein biosynthesis
inhibition assays] were developed in identical condi-
tions in order to compare the toxic action of the
two proteins against SW1222 cells. Figure 7 displays
the viability curves obtained after incubation with
A33-positive cells for 72 h. The IC50 value was
0.5 lM for IMTXA33aS and 3.5 lM for scFvA33T1.
When protein biosynthesis inhibition was analyzed in
the same conditions the IC50 values obtained were
30 nM and > 5 lM, respectively.
To assess the relationship between the cytotoxic effi-
ciency and the intracellular pathway followed by the
immunoconjugates IMTXA33aS or scFVA33T1, new
in vitro cytotoxicity assays were performed including
bafilomycin or brefeldin A as inhibitors of the lyso-
somal and Golgi functions, respectively [50,51]. As
expected, scFvA33T1 toxicity was dramatically
increased when bafilomycin was added, due to
A
B
Fig. 3. Immunofluorescence confocal
microscopy images of SW1222 cells
incubated for 2 h with IMTXA33aS-555 or
scFvA33T1-555 to analyze colocalization
with endosomes. (A) Two sets of images
for each immunoconjugate are shown.
Columns (from left to right) correspond to
nuclei labeled with DAPI, early endosomes
labeled with anti-EEA1 and GAR-Alexa
488, IMTXA33aS-555 or scFvA33T1-555
and images corresponding to merging of
the three channels. Arrows indicate some
sites of colocalization. (B) Quantitative
colocalization analysis as indicated in
Materials and methods.
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inhibition of recycling in the lysosomes, with an IC50
value of 70 nM (Fig. 8), while no effect was observed
when brefeldin A was added. On the other hand, IM-
TXA33aS showed a significantly diminished toxicity
when brefeldin A was added, with an increase in the
IC50 value up to 0.5 lM. However, no effect was
observed in this case after the addition of bafilomycin
(Fig. 8).
A
B
Fig. 4. Immunofluorescence confocal
microscopy images of SW1222 cells
incubated for 4 and 16 h with scFvA33T1-
555 in the absence or presence of
bafilomycin at 5 ngmL1 to analyze
colocalization with lysosomes. (A) Images
correspond to (columns from left to right)
nuclei labeled with DAPI, lysosomes
labeled with Lysotracker, scFvA33T1-555
and merging of the three channels.
Arrows indicate some sites of
colocalization observed. (B) Quantitative
colocalization analysis as indicated in
Materials and methods.
A
B
Fig. 5. Immunofluorescence confocal
microscopy images of SW1222 cells
incubated for 4 and 16 h with IMTXA33aS-
555 to analyze colocalization with
lysosomes. (A) Images correspond to
(columns from left to right) nuclei labeled
with DAPI, lysosomes labeled with
Lysotracker, IMTXA33aS-555 and merging
of the three channels. (B) Quantitative
colocalization analysis as indicated in
Materials and methods.
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AB
Fig. 6. Immunofluorescence confocal
microscopy images of SW1222 cells
incubated for 4 and 16 h with IMTXA33aS-
555 or scFvA33T1-555 to analyze
colocalization with the Golgi apparatus. (A)
Images correspond to (columns from left
to right) nuclei labeled with DAPI, Golgi
labeled with agglutinin, IMTXA33aS-555 or
scFvA33T1-555 and merging of the three
channels. Arrows indicate some sites of
colocalization. (B) Quantitative
colocalization analysis as indicated in
Materials and methods.
A B
Fig. 7. Viability assay of SW1222 cells
incubated for 72 h with IMTXA33aS
(upper panel) or scFvA33T1 (bottom
panel). The graphs on the left (A)
correspond to the MTT assays, while the
ones on the right (B) are protein
biosynthesis inhibition experiments. The
dotted line corresponds to the IC50 values,
being 0.5 lM for IMTXA33aS and 3.5 lM
for scFvA33T1 (MTT assays). The protein
biosynthesis experiments yielded IC50
values of 0.03 lM for IMTXA33aS and
~ 10 lM for scFvA33T1.
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Discussion
Over the last few years, evidence has accumulated to
describe how the efficiency of immunotoxins depends
on a large number of conditions [23,52,53]. These
include the nature and reaction mechanism of the toxic
domain [29,54,55], the type of tumor [28,56,57], the
specificity and mechanism of binding [58,59] and the
innate toxicity of the construct once the immunoconju-
gate reaches the tumor [53,60]. Within this idea, under-
standing the toxin intracellular pathway is crucial for
improving the immunotoxin efficiency [4,20].
Consequently, in this report we have studied two
immunoconjugates with the same binding domain but
two different toxic moieties. Both showed identical
specific binding to GPA33-positive cells, as described
previously using flow cytometry and confocal micros-
copy [13,44]. Now it is shown how both immunoconju-
gates enter via early endosomes, one of the most
common means of internalization [61]. This transit is
indeed brief, as shown by the quick disappearance of
the corresponding fluorescence signal related to endo-
some colocalization. However, these similarities disap-
pear when the intracellular pathway followed by the
toxic domain is analyzed (Fig. 9). Thus, the a-sarcin
based immunotoxin displays a clear preference for the
endosome–Golgi apparatus pathway and translocates
into the cytosol directly either from the endosomes or
the Golgi apparatus, most probably as a result of the
ability of a-sarcin to interact with negatively charged
membranes [62,63]. Interestingly, the construction con-
taining RNase T1 was found both in the lysosomes
and in the Golgi apparatus. In this case, the incapacity
of RNase T1 to interact with membranes would hinder
its release to the cytosol from the Golgi, as can be
inferred by the increase in the colocalization fluores-
cence signal. Furthermore, the use of the lysosomal
route would involve the proteolytic degradation of the
immunoRNase, decreasing its cytotoxic efficacy.
These interpretations are further supported by the
results obtained regarding the cytotoxic efficiency in
the presence of brefeldin A or bafilomycin. Thus, when
the vesicle transport through the Golgi apparatus is
impaired due to the addition of brefeldin A, the cyto-
toxicity efficiency of IMTXA33aS is diminished. How-
ever, when lysosomal recycling is the function
disrupted, by bafilomycin, a significantly increased
cytotoxicity was observed in the case of scFvA33T1.
Initially, the differences observed between both im-
munoconjugates in terms of antitumoral activity were
explained by the exquisite specificity of a-sarcin
against ribosomes [13,42] in contrast with the much
less specific action of RNase T1 [43,44]. That is, a pri-
ori many fewer a-sarcin molecules would be needed to
induce cell death. In fact, it has been estimated that
just one molecule of this ribotoxin would be enough to
efficiently kill one cell [64]. However, the results pre-
sented now suggest a more complex scenario where the
intracellular pathway followed by each toxic moiety
would also strongly influence the lethality of each im-
munoconjugate. The differences observed in their
intracellular trafficking pathways are in fact in good
agreement with the results of their cytotoxic action
since IMTXA33aS was found to be 7-fold higher. In
this sense, both endosomes and Golgi apparatus inner
A
B
Fig. 8. Viability assay of SW1222 cells incubated for 72 h with
scFvA33T1 (A) or IMTXA33aS (B) and brefeldin A or bafilomycin.
(A) MTT viability assay of SW1222 cells incubated with scFvA33T1
(●), scFvA33T1 + bafilomycin (□) and scFvA33T1 + brefeldin A (D),
with IC50 values of 70 nM for scFVA33T1 + bafilomycin and > 1 lM
for scFvA33T1 alone or with brefeldin A. (B) Protein biosynthesis
inhibition assay of SW1222 cells incubated with IMTXA33aS (●),
IMTXA33aS + bafilomycin (□) and IMTXA33aS + brefeldin A (D),
with IC50 values of 20–30 nM for IMTXA33aS alone or with
bafilomycin and 0.5 lM for IMTXA33aS with brefeldin A. The
dashed line indicates the 50% level of protein biosynthesis
inhibition used to calculate the IC50 values.
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membranes are rich in negative charges [65–68]. This
negative charge environment most probably contrib-
utes to a-sarcin translocation since it is well known
that this protein takes advantage of the presence of
negative acidic phospholipids to enter its target cells
[42,62]. Thus, a-sarcin delivery to the cytosol could be
achieved directly from endosomes or from the Golgi
apparatus. However, RNase T1, a protein with an
acidic pI value [43,49], would not be able to interact
with the endosome or Golgi membranes, resulting in
an impairment of its release into the cytosol, favoring
also recycling and degradation in the lysosomes or
driving to the late Golgi.
In summary, the data reported here elucidate the
different pathways followed by two thoroughly studied
RNases when integrated into an antitumoral immuno-
conjugate and how their innate features affect the toxic
behavior of the two immunotoxins assayed. Therefore,
a-sarcin based immunotoxins exhibit greater antitu-
moral activity than those based on RNase T1 not only
because of the higher intrinsic lethal activity of a-sar-
cin against ribosomes but also because it uses the
Golgi intracellular pathway to reach the cytosol in a
much more efficient way.
Materials and methods
Cell line culture
Colon carcinoma SW1222 cells were used as a standardized
GPA33-positive cellular line [13,44]. This cell line was
grown as described previously [44] in Dulbecco’s modified
Eagle’s medium containing glutamine (300 mgmL1),
50 UmL1 of penicillin and 50 mgmL1 of streptomycin.
This medium was supplemented with 10% fetal bovine
serum. Incubation was performed at 37 °C in a humidified
atmosphere (CO2 : air, 1 : 9 v/v). Harvesting and propaga-
tion of cultures were routinely performed by trypsinization.
The number of cells used was determined in all assays by
using a hemocytometer.
Alexa 555 labeling of IMTXA33aS and scFvA33T1
The absence of primary amine groups in the complemen-
tary determinant regions of the scFvA33 was previously
checked to prevent modifications that could result in defec-
tive binding [69]. Then, the Alexa Fluor 555 Protein Label-
ing Kit (Invitrogen, Carlsbad, CA, USA) was used to label
the proteins by incubating 2.6 nmol of IMTXA33aS or
scFvA33T1 with 44.6 nmol of Alexa 555 for 15 min at
room temperature. The buffer used was 0.1 M sodium
bicarbonate, pH 7.5 for the immunotoxin and pH 8.0
for the immunoRNase. Both Alexa 555 conjugates (IM-
TXA33aS-555 and scFvA33T1-555) were purified using the
resin provided with the kit. Finally, the degree of labeling
was calculated according to the kit instructions.
Far-UV circular dichroism
Far-UV CD spectra were obtained on a Jasco 715 spec-
tropolarimeter at 50 nmmin1 scanning speed as
described before [70]. Proteins were used at 0.15 mgmL1
in PBS. Cells of 0.1 cm optical path were employed.
At least four spectra were averaged to obtain the final
data.
Fig. 9. Scheme representing the different
intracellular pathways that can be followed
by an immunoconjugate to release its
toxic cargo into the cytosol.
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Fluorescence microscopy
SW1222 cells were trypsinized, seeded at 8 9 105 cellswell1
over cover-glasses placed into a 24-well plate, and incubated
at 37 °C overnight. Cells were then treated with IM-
TXA33aS-555 or scFvA33T1-555, at 25 lgmL1, for differ-
ent periods of time: 2 h for endosome colocalization, 4 or
16 h for lysosomes/Golgi and 16 h for overall internalization
assays. To confirm colocalization of scFvA33T1 with lyso-
somes, bafilomycin at 5 ngmL1 was added together with
the immunoRNase, when necessary. To visualize the plas-
matic membrane, cells were incubated with anti-CD44 mAb
[71]. Then, medium was removed and cells were fixed for
15 min with PBS containing 3% (v/v) p-formaldehyde, fol-
lowed by a 15-min incubation in PBS containing 50 mM
ammonium chloride. Cells were permeabilized with digitonin
at 0.01% (w/v) in PBS for 30 min, followed by PBS contain-
ing 1.0% (w/v) BSA for 1 h. For organelle labeling different
probes were used: early endosomes were labeled with anti-
EEA1 (Abcam, Cambridge, UK), lysosomes with Lysotrac-
ker (Life Technologies, Madrid, Spain) and Golgi apparatus
with wheat germ agglutinin (Life Technologies), following
the provider’s instructions. DAM-Alexa 647 and goat anti-
rabbit (GAR)-Alexa 488 were used as secondary antibodies.
Finally, nuclei were labeled with 10 lL of Prolong Gold with
4,6-diamidino-2-phenylindole (DAPI) (Life Technologies).
All incubations were performed at room temperature and
the final preparations were kept at 4 °C until further use. A
Leica TCS SP2 confocal microscope and LCS LITE software
were used to obtain the images. Starting at the basal zone of
the cells and ending at the apical, 10 different images were
taken along the z-axis for each preparation. Images corre-
spond to slices 4–6, i.e. the optical planes corresponding to
the internal content of the analyzed cells. For quantitative
colocalization analysis, IMAGEJ software was used to calculate
the Pearson correlation coefficient and the overlap coefficient
according to Mander, which refer to the correlation of the
intensity distribution between channels and true degree of
colocalization, respectively [72].
MTT viability assay
Cell viability was evaluated by MTT using the Cell Prolif-
eration Kit I (Roche, Basel, Switzerland). This assay is
based on the cleavage of the yellow tetrazolium salt MTT
to purple formazan crystals by metabolic active cells.
Trypsinized 5 9 103 cellswell1 were seeded into a 96-well
plate and incubated for 24 h at 37 °C in a humidified
atmosphere. Then, the medium was removed and replaced
with a new one containing IMTXA33aS or scFvA33T1 at
different concentrations in 200 lL final volume. After an
incubation time of 24 h, cells were further incubated with
MTT at 0.5 mgmL1 for 2 h at 37 °C, following the MTT
kit instructions. Once this incubation was finished, the solu-
bilization buffer was added and viability was measured in
terms of absorbance at 550 nm. A higher amount of viable
cells corresponds to higher A550 values. Thus, readings
obtained for cells incubated only with medium, in the
absence of either IMTXA33aS or scFvA33T1, were taken
as 100% viability. When required, brefeldin A or bafilomy-
cin at 1 or 5 ngmL1 respectively were added together
with the immunoconjugates. Controls with brefeldin A or
bafilomycin without the immunoconjugates were performed
to consider drug related toxicity. Results shown are the
average of four independent assays.
Protein biosynthesis inhibition
Ribotoxins exert their cellular cytotoxicity by inactivating
ribosomes, leading to protein biosynthesis inhibition and
cellular death [42]. Thus, protein biosynthesis is the activity
routinely used to evaluate the toxic effect of this family of
proteins [49,63]. Consequently, to evaluate the effect of
IMTXA33aS or scFvA33T1, cells were seeded into 96-well
plates at 1 9 104 cellswell1 in culture medium and main-
tained under standard culture conditions for 36 h. Then the
monolayer cultures were incubated with 0.2 mL of fresh
medium in the presence of different concentrations of
IMTXA33aS or scFvA33T1. Following 72 h of incubation
at 37 °C, the medium was removed and replaced with fresh
medium supplemented with 1 lCiwell1 of L-[4,5-3H]-leu-
cine (166 Cimmol1; GE Healthcare UK Ltd, Buckingham-
shire, UK). After an additional incubation of 6 h, this
medium was also removed; cells were fixed with 5.0% (w/v)
trichloroacetic acid and washed three times with cold etha-
nol. The resulting dried pellet was dissolved in 0.2 mL of
0.1 M NaOH containing 0.1% SDS, and its radioactivity was
counted on a Beckman LS3801 liquid scintillation counter.
The results were expressed as percentage of the radioactivity
incorporated in control samples incubated without either of
the two immunoconjugates to calculate IC50 values (protein
concentration inhibiting 50% protein synthesis) in the cyto-
toxicity assays. When required, brefeldin A or bafilomycin at
1 or 5 ngmL1 respectively was added together with the
immunoconjugates. Controls with brefeldin A or bafilomycin
without the immunoconjugates were performed to consider
drug related toxicity. Three independent replicate assays
were conducted to calculate the average IC50 values.
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